Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Tremelimumab, Tremelimumab (Regimen 1)
Tremelimumab monotherapy · 1 trial · 3 indications
Objective response rate (ORR) during the initial tremelimumab monotherapy phase was assessed by the site Investigator using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) and was defined as the percentage of patients with a confirmed overall response of complete response (CR) or partial response (PR) and was based on all treated patients who had measurable disease at baseline (Day 1). 95% confidence intervals (CIs) were calculated using the Clopper Pearson method.
| Arm | Type | Description |
|---|---|---|
| treme mono to be sequenced to MEDI4736 mono or combination | EXPERIMENTAL | tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD) |
| Name | Type | Description |
|---|---|---|
| Tremelimumab monotherapy | BIOLOGICAL | IV infusion |
| MEDI4736 monotherapy | BIOLOGICAL | IV infusion |
| MEDI4736 + tremelimumab combination therapy | BIOLOGICAL | IV infusion |
Inclusion Criteria: 1\. histologically or cytologically documented solid tumor malignancies, including but not limited to 1 of the following: UBC, Metastatic PDAC, TNBC; Are intolerant, are ineligible for, or have refused treatment with standard first-line therapy; 2. At least 1 lesion, not previou...
Tremelimumab is an investigational antibody being studied in oncology. It is being evaluated for combined hepatocellular and cholangiocarcinoma, urothelial bladder cancer, non small cell lung cancer, urothelial carcinoma, colorectal cancer, and advanced solid malignancies. It is typically studied in combination with durvalumab.
Tremelimumab is a monoclonal antibody that targets CTLA-4, a protein on T cells that downregulates immune responses. By blocking CTLA-4, tremelimumab is designed to enhance the immune system's ability to attack cancer cells. It is being developed by AstraZeneca.
Tremelimumab is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical trials of tremelimumab across multiple cancer types, often in combination with durvalumab.
Tremelimumab is in Phase 2 clinical development. It is not yet approved by the FDA and remains investigational. Several Phase 2 trials are ongoing or completed, including studies in colorectal cancer and urothelial carcinoma.
Tremelimumab is being studied in several trials. NCT02870920 is a completed Phase 2 trial in colorectal cancer. NCT03317158 is an active Phase 1 trial in urothelial carcinoma. NCT03557918 is a completed Phase 2 trial in urothelial cancer. NCT06855225 is a Phase 2 trial in combined hepatocellular-cholangiocarcinoma.
Yes, Tremelimumab is also known as Tremelimumab (Regimen 1). This alternative name is used in clinical trial contexts to distinguish a specific dosing schedule or combination approach. Both names refer to the same investigational drug.